CBIO · Crescent Biopharma, Inc.
AI read · Good for CBIO
The AI's read
This gives Crescent more chances to test whether its drugs work across different cancers and with other treatments. The company has also cleared a U.S. step to begin testing another drug in people. But the update reports no new patient-response results. Those results are expected later, and larger studies depend on results and further talks with regulators.